Disorders of coagulation in stroke

Seminars in Neurology

Volumn 26, Issue 1, 2006, Pages 57-64

  Waddy, Salina P ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Protein; Stroke

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PROTEIN C; PROTEIN S; PROTHROMBIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN VEIN; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS; VEIN THROMBOSIS;

EID: 33244467017     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933309     Document Type: Review

References (88)

1. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003; 25:1220-1228
2. Haberl RL, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders. Cerebrovasc Dis 1995;5:391-396
3. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995;15: 783-785
4. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003;101:20-30
5. Lutze G, Frick U, Topfer G, Urbahn H. Hereditaere Dysprothrombinaemie mit geringer Blutungsneigung (Prothrombin Magdeburg). Dtsch Med Wochenschr 1989;114: 288-292
6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
7. Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003;1:3-9
8. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:21158-21166
9. Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003;1:3-9
10. R506Q mutation. Thromb Haemost 1996;76:208-214
11. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999;93:2552-2558
12. Ridker PM, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917
13. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15:783-785
14. Press RD, Liu X-Y, Beamer N, et al. Ischaemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-48
15. Castaman G, Tosetto A, Ruggeri M, Rodeghiero F. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Br J Haematol 1999;106: 232-236
16. Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC-cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004;103:4173-4179
17. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90: 1552-1557
18. Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997;99:257-261
19. Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998;91:1140-1144
20. Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91:1135-1139
21. Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001;28:389-392
22. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost 2000;83:1-2
23. Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003;33:395-400
24. Sebire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005;128:477-489
25. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998;91:1140-1144
26. Kalafatis M, Simioni P, Tormene D, et al. Isolation and characterization of an anti-factor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 2002;99:3985-3992
27. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995;74:1198-1199
28. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996;7:761-765
29. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;73:876-889
30. Reitsma PH. Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res 1996;24:157-159
31. Gladson CL, Scharrer I, Hach V, et al. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988;59:18-22
32. Grewal RP, Goldberg MA. Stroke in protein C deficiency. Am J Med 1990;89:538-539
33. Kohler J, Kasper J, Witt I, et al. Ischaemic stroke due to protein C deficiency. Stroke 1990;21:1077-1080
34. Camerlingo M, Finazzi G, Caato L, et al. Inherited protein C deficiency and non-haemorrhagic arterial stroke in young adults. Neurology 1991;41:1371-1373
35. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997;126:638-644
36. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353-2358
37. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869-31880
38. Nicolaes GAF, Tans G, Christella M, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995;270:21158-21166
39. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993;268:2872-2877
40. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994;269:21051-21058
41. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995;86:1062-1071
42. van Wijnen M, Stam JG, van't Veer C, et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996;76:397-403
43. Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991;66:49-61
44. van de Poel RH, Meijers JC, Bouma BN. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost 2001;85:761-765
45. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103:1192-1201
46. Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of mutations-summary of the first update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2000;84:918
47. Bertina RM. Nomenclature proposal for protein S deficiency. XXXVI Annual meeting of the Scientific and Standardization Committee of the ISTH. Barcelona, Spain; 1990
48. Israels SJ, Seshia SS. Childhood stroke associated with protein C or protein S deficiency. J Pediatr 1987;111:562-564
49. Barinagarrementeria F, Cant A, Cant-Brio C, et al. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke 1994;25:287-290
50. Mayer SA, Sacco RL, Hurlet-Jensen A, Shi T, Mohr JP. Free protein S deficiency in acute ischemic stroke: a case-control study. Stroke 1993;24:224-227
51. Kurnik K, Kosch A, Sträter R, et al. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke. Stroke 2003;34:2887-2892
52. Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology 1992;42:1029-1033
53. Golub BM, Sibony PA, Coller BS. Protein S deficiency associated with central retinal artery occlusion. Arch Ophthal 1990;108:918
54. Hakimi KN, Massagli TL. Anterior spinal artery syndrome in two children with genetic thrombotic disorders. J Spinal Cord Med 2005;28:69-73
55. Espinosa-Parrilla Y, Morell M, Souto JC, et al. Protein S gene analysis reveals the presence of a cosegregating mutation in most pedigrees with type I but not type III PS deficiency. Hum Mutat 1999;14:30-39
56. Makris M, Leach M, Beauchamp NJ, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000;95:1935-1941
57. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost 1997;78:351-356
58. Restrepo L, McArthur J. Stroke and HIV infection. Stroke 2003;34:e176-e177
59. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993;81:1801-1807
60. Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost 2004;10:19-25
61. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-6505
62. Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975;250:8883-8888
63. Seegers WH, Holt E. An antithrombin reaction related to prothrombin activation. Am J Physiol 1954;176:97
64. Biggs R, Denson KW, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor X and heparin. Br J Haematol 1970;19:283-305
65. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973;246:355-357
66. Stead N, Kaplan A, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976;251:6481-6488
67. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992;267:12528-12538
68. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol 1995; 2:96-113
69. Vomberg PP, Breederveld C, Fluery P, Arts WF. Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics 1987;18:42-44
70. Simioni P, Zanardi S, Saracino A, et al. Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. J Med 1992;23:61-64
71. Arima T, Motomura M, Nishiura Y, et al. Cerebral infarction in a heterozygous with variant antithrombin III. Stroke 1992; 23:1822-1825
72. Graham JA, Daly HM, Carson PJ. Antithrombin III deficiency and cerebrovascular accidents in young adults. J Clin Pathol 1992;45:921-922
73. Martinez HR, Rangel Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke 1993;24:19-25
74. Barinagarrementeria F, Cantu-Brito C, De La Pena A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study. Stroke 1994;25:287-290
75. Ernerudh J, Olsson JE, von Schenck H. Antithrombin-III deficiency in ischemic stroke. Stroke 1990;21:967
76. Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998;245:21-25
77. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917
78. Markus HS, Hambley H. Neurology and the blood: haematological abnormalities in ischaemic stroke. J Neurol Neurosurg Psychiatry 1998;64:150-159
79. Haberl RL, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders. Cerebrovasc Dis 1995;5:391-396
80. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995;15: 783-785
81. Press RD, Liu X, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-48
82. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker R. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001;32:1793-1799
83. Jerrard-Dunne P, Evans A, McGovern R, et al. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke 2003; 34:1821-1827
84. Martinez HR, Rangel Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke 1993;24:19-25
85. Barinagarrementeria F, Cantu-Brito C, De La Peria A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke 1994;25:287-290
86. Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998;245:21-25
87. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420-423
88. Shen YM, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004;10:277-280